GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.